Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NMT2 | O60551 | 1/20 | 0.57 |
| ▸ | NMT1 | P30419 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049355 | 0.91 | MAPT (0.61) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL18997452 | 0.88 | MAPT (0.59) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL19002792 | 0.86 | MAPT (0.57) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL21900477 | 0.86 | MAPT (0.57) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL21740777 | 0.86 | MAPT (0.57) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL3234894 | 0.85 | KDM4E (0.68) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL11075264 | 0.84 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL20669637 | 0.82 | KDM4E (0.65) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL21940199 | 0.82 | KDM4E (0.65) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 | |
| SCHEMBL21940599 | 0.80 | KDM4E (0.62) | ALDH1A1KDM4ESMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885KDM4E 3392/4885SMN1; SMN2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.